SynthesisWorld journal of gastroenterology2012
Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.
Synthesis in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Perforated and bleeding peptic ulcer: WSES guidelines.World journal of emergency surgery : WJES · 2020Guideline
- Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.The American journal of gastroenterology · 2017Trial
- Diagnosis, Treatment Patterns and Eradication Success forJGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Article
- Update on the second-line treatment ofTherapeutic advances in gastroenterology · 2023Review
- Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens?Gut pathogens · 2022Article
- Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.Digestive diseases and sciences · 2022Article
- Study on the value of antibiotic-resistant gene detection inExperimental and therapeutic medicine · 2022Article
- Optimization Strategies Aimed to Increase the Efficacy ofMolecules (Basel, Switzerland) · 2020Review
- Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance ofAntibiotics (Basel, Switzerland) · 2020Article
- Clinical characterization of Helicobacter pylori infected patients 15 years after unsuccessful eradication.PloS one · 2020Article
- Second-line rescue treatment ofWorld journal of gastroenterology · 2018Review
- Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.Helicobacter · 2017Article
- Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication ofGut and liver · 2017Article
- Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.BMC gastroenterology · 2016Article
- Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.Clinics (Sao Paulo, Brazil) · 2015Article
- Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection.Current treatment options in gastroenterology · 2014Article
- Treatment of Helicobacter pylori infection: Past, present and future.World journal of gastrointestinal pathophysiology · 2014Review
- Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.World journal of gastroenterology · 2014Article
- Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide prevalence of Helicobacter pylori (H. pylori) infection is approximately 50%, with the highest being in developing countries. We compared cure rates and tolerability (SE) of second-line anti-H. pylori levofloxacin/amoxicillin (LA)-based triple regimens vs standard quadruple therapy (QT). An English language literature search was performed up to October 2010. A meta-analysis was performed including randomized clinical trials comparing 7- or 10-d LA with 7-d QT. In total, 10 articles and four abstracts were identified. Overall eradication rate in LA was 76.5% (95% CI: 64.4%-97.6%). When only 7-d regimens were included, cure rate was 70.6% (95% CI: 40.2%-99.1%), whereas for 10-d combinations, cure rate was significantly higher (88.7%; 95% CI: 56.1%-109.9%; P < 0.05). Main eradication rate for QT was 67.4% (95% CI: 49.7%-67.9%). The 7-d LA and QT showed comparable efficacy [odds ratio (OR): 1.09; 95% CI: 0.63-1.87], whereas the 10-d LA regimen was significantly more effective than QT (OR: 5.05; 95% CI: 2.74-9.31; P < 0.001; I(2) = 75%). No differences were reported in QT eradication rates among Asian and European studies, whereas LA regimens were more effective in European populations (78.3% vs 67.7%; P = 0.05). Incidence of SE was lower in LA therapy than QT (OR: 0.39; 95% CI: 0.18-0.85; P = 0.02). A higher rate of side effects was reported in Asian patients who received QT. Our findings support the use of 10-d LA as a simple second-line treatment for H. pylori eradication with an excellent eradication rate and tolerability. The optimal second-line alternative scheme might differ among countries depending on quinolone resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.